Перейти
на сайт журнала "Врач" |
Перейти на сайт журнала "Медицинская сестра"
|
Перейти на сайт журнала "Фармация"
|
Перейти на сайт журнала "Молекулярная медицина"
|
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
|
Журнал включен в российские и международные библиотечные и реферативные базы данных
ВАК (Россия)
|
РИНЦ (Россия)
|
Эко-Вектор (Россия)
|
CHALCONE ANALOGUES AS POTENTIAL MEDICINES OF PATHOGENETIC THERAPY OF ALZHEIMER'S DISEASE: IN VITRO SCREENING
DOI: https://doi.org/10.29296/25877313-2024-02-05
Issue:
2
Year:
2024
Introduction. Alzheimer's disease is one of the most common forms of dementia, the pathogenesis of which is based on the accumulation of β–amyloid plaques in brain structures and the development of cholinergic deficiency.
The aim of the study was to evaluate the effect of chalcone analogues on the change in acetylcholinesterase activity and the process of β-amyloid aggregation in vitro.
Material and methods. The tested compounds were six bis-substituted chalcone analogues, which were dissolved in dimethylsulfoxide during the analysis to obtain double dilutions. The effect of the studied substances on the activity of acetylcholinesterase was evaluated by the modified Ellman method. The change in the aggregation process of β-amyloid particles was determined in reaction with congo red after 3, 6 and 9 days of incubation. Based on the obtained results of the «% inhibition- concentration» relationships, the IC50 index was calculated, which was expressed in mmol/ml.
Results. In the course of the study, it was shown that the analyzed chalcone analogues inhibit the aggregation of β-amyloid particles starting from the 6th day of incubation with a maximum on the 9th day. At the same time, the compounds that showed the highest level of activity were trimethoxy-substituted substances under the codes AZBAX4 and AZBAX6, whose IC50 on the 9th day of the study was 21.4±0.928 mmol/ml and 32.4±0.456 mmol/ml, respectively. Also, a high level of anticholinesterase properties was established for these compounds with IC50 of 35.9±0.991mmol/ml and 25.1±0.261 mmol/ml, respectively. The rest of the tested compounds showed a lower level of activity.
Conclusion. The study showed that chalcone analogues under the codes AZBAX4 and AZBAX6 inhibit the activity of acetylcholinesterase and the pro-cess of aggregation of β-amyloid in vitro, which makes these compounds promising for further study in order to develop medicines for the pathogenet-ic treatment of Alzheimer's disease.
Keywords:
Alzheimer's disease
β-amyloid
acetylcholinesterase
chalcones.
References:
- Khan S., Barve K.H., Kumar M.S. Recent Advancements in Patho-genesis, Diagnostics and Treatment of Alzheimer's Disease. Curr Neuropharmacol. 2020; 18(11): 1106‒1125. DOI: 10.2174/1570159X18666200528142429.
- Barage S.H., Sonawane K.D. Amyloid cascade hypothesis: Patho-genesis and therapeutic strategies in Alzheimer's disease. Neuropep-tides. 2015; 52: 1‒18. DOI: 10.1016/j.npep.2015.06.008.
- Brum W.S., de Bastiani M.A., Bieger A., et al. A three-range ap-proach enhances the prognostic utility of CSF biomarkers in Alz-heimer's disease. Alzheimers Dement (N Y). 2022; 8(1): e12270. Published 2022 Mar 13. DOI: 10.1002/trc2.12270.
- Hampel H., Mesulam M.M., Cuello A.C., et al. The cholinergic sys-tem in the pathophysiology and treatment of Alzheimer's disease. Brain. 2018; 141(7): 1917‒1933. DOI: 10.1093/brain/awy132.
- Podtelezhnikov A.A., Tanis K.Q., Nebozhyn M., et al. Molecular in-sights into the pathogenesis of Alzheimer's disease and its relation-ship to normal aging. PLoS One. 2011; 6(12): e29610. DOI: 10.1371/journal.pone.0029610.
- Ferreira-Vieira T.H., Guimaraes IM, Silva F.R., Ribeiro F.M. Alz-heimer's disease: Targeting the Cholinergic System. Curr Neuro-pharmacol. 2016; 14(1): 101‒115. DOI: 10.2174/1570159x13666150716165726.
- Yu T.W., Lane H.Y., Lin C.H. Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review. Int J Mol Sci. 2021 Jul 30; 22(15): 8208. DOI: 10.3390/ijms22158208. PMID: 34360973; PMCID: PMC8348485.
- Wang W., Zhao C., Zhu D., Gong G., Du W. Inhibition of amyloid peptide fibril formation by gold-sulfur complexes. J InorgBiochem. 2017; 171: 1‒9. DOI: 10.1016/j.jinorgbio.2017.02.021.
- Durmaz Ş., Evren A.E., Sağlık B.N., et al. Synthesis, anticholines-terase activity, molecular docking, and molecular dynamic simula-tion studies of 1,3,4-oxadiazole derivatives. Arch Pharm (Wein-heim). 2022; 355(11): e2200294. DOI: 10.1002/ardp.202200294.
- Thapa A., Jett S.D., Chi E.Y. Curcumin Attenuates Amyloid-β Ag-gregate Toxicity and Modulates Amyloid-β Aggregation Pathway. ACS Chem Neurosci. 2016; 7(1): 56‒68. DOI: 10.1021/acschemneuro.5b00214.
- Tello-Franco V., Lozada-García M.C., Soriano-García M. Exper-imental and computational studies on the inhibition of acetylcholin-esterase by curcumin and some of its derivatives. Curr Comput Aided Drug Des. 2013; 9(2): 289‒298. DOI: 10.2174/15734099113099990007.